Macrocyclic bisindolylmaleimides
1−4 have been identified as competitive
reversible inhibitors of
PKC β1 and β2 and are being advanced to the
clinic for evaluation as a treatment of retinopathy
associated with diabetic complications. Highly convergent and
stereoselective syntheses of 1−4
have been developed. The key synthetic step involves
intermolecular alkylation of symmetrical
bisindolylmaleimide 9 with chiral bisalkylating agent
8c and is amenable to the preparation of
multikilogram quantities of these compounds. The synthetic
sequence to 1, the most active
compound, proceeds in 11 steps and 26% overall yield (>98% ee) from
(R)-1-chloro-2,3-propanediol.
No chromatographic purifications are required throughout the
process and the final product is
isolated in >97% purity after crystallization from DMF/MeOH.
Synthesis of 1−4 by
intramolecular
alkylation proved less efficient, requiring 17 steps and affording
1−4 in lower overall yields of
6.0−8.5%.